Insider · CIK 0001421050

Mammen Mathai

Reports to the SEC for 5 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001421050

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-06-11	TXG10x Genomics, Inc.A Award	Director	AAward	+8,649 sh	—	—	180,259
2023-06-14	TXG10x Genomics, Inc.A Award	Director	AAward	+1,865 sh	—	—	171,610
2023-06-14	TXG10x Genomics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+4,661 sh	—	—	4,661
2023-05-11	TXG10x Genomics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+200K sh	$1.16	+$232K	202,745
2023-05-11	TXG10x Genomics, Inc.S Sale	Director	SSale	−33K sh	$52.82	−$1.74M	169,745
2023-05-11	TXG10x Genomics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−200K sh	—	—	0
2022-06-15	TXG10x Genomics, Inc.A Award	Director	AAward	+2,120 sh	—	—	2,745
2022-06-15	TXG10x Genomics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+5,300 sh	—	—	5,300
2022-02-15	JNJJOHNSON & JOHNSONM Exercise/Conversion	EVP, Pharm, R&D	MExercise/Conversion	+7,740 sh	—	—	45,300
2022-02-15	JNJJOHNSON & JOHNSONF Tax Payment	EVP, Pharm, R&D	FTax Payment	−3,366 sh	$165.89	−$558K	41,934
2022-02-15	JNJJOHNSON & JOHNSON · Performance Share UnitsM Exercise/Conversion	EVP, Pharm, R&D	MExercise/Conversion	−7,740 sh	—	—	737
2022-02-14	JNJJOHNSON & JOHNSONM Exercise/Conversion	EVP, Pharm, R&D	MExercise/Conversion	+7,418 sh	—	—	39,895
2022-02-14	JNJJOHNSON & JOHNSONF Tax Payment	EVP, Pharm, R&D	FTax Payment	−2,335 sh	$168.85	−$394K	37,560
2022-02-14	JNJJOHNSON & JOHNSON · Restricted Share UnitsM Exercise/Conversion	EVP, Pharm, R&D	MExercise/Conversion	−7,418 sh	—	—	0
2022-02-14	JNJJOHNSON & JOHNSON · Employee Stock Options (Right to Buy)A Award	EVP, Pharm, R&D	AAward	+38.7K sh	$165.89	+$6.43M	38,736
2022-02-14	JNJJOHNSON & JOHNSON · Restricted Share UnitsA Award	EVP, Pharm, R&D	AAward	+3,922 sh	—	—	3,922
2021-06-11	TXG10x Genomics, Inc.A Award	Director	AAward	+625 sh	—	—	625
2021-06-11	TXG10x Genomics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+1,563 sh	—	—	1,563
2020-06-15	TXG10x Genomics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+4,432 sh	—	—	4,432
2019-09-16	TXG10x Genomics, Inc. · Stock Option (right to buy)J Other	Director	JOther	−200K sh	—	—	0
2019-09-16	TXG10x Genomics, Inc. · Stock Option (right to buy)J Other	Director	JOther	+200K sh	—	—	200,000
2016-03-15	TBPHTheravance Biopharma, Inc.A Award	SVP, Research & Development	AAward	+90K sh	—	—	288,111
2016-02-20	TBPHTheravance Biopharma, Inc.F Tax Payment	SVP, Research & Development	FTax Payment	−19.8K sh	$15.65	−$311K	198,111
2015-11-20	TBPHTheravance Biopharma, Inc.F Tax Payment	SVP, Research & Development	FTax Payment	−934 sh	$17.17	−$16K	217,955
2015-08-20	TBPHTheravance Biopharma, Inc.F Tax Payment	SVP, Research & Development	FTax Payment	−934 sh	$12.98	−$12.1K	218,889
2015-06-02	TBPHTheravance Biopharma, Inc.F Tax Payment	SVP, Research & Development	FTax Payment	−7,360 sh	$13.83	−$102K	219,823
2015-05-20	TBPHTheravance Biopharma, Inc.F Tax Payment	SVP, Research & Development	FTax Payment	−673 sh	$14.24	−$9,583.52	227,183
2015-02-20	TBPHTheravance Biopharma, Inc.F Tax Payment	SVP, Research & Development	FTax Payment	−674 sh	$19.52	−$13.2K	227,856
2015-02-05	TBPHTheravance Biopharma, Inc.A Award	SVP, Research & Development	AAward	+130K sh	—	—	228,530
2014-11-20	TBPHTheravance Biopharma, Inc.F Tax Payment	SVP, Research & Development	FTax Payment	−658 sh	—	—	80,492
2014-10-08	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)A Award	SVP, Research & Development	AAward	+170K sh	—	—	170,000
2014-08-20	INVAInnoviva, Inc.F Tax Payment	SVP, Research & Early Clin Dev	FTax Payment	−3,261 sh	$22.76	−$74.2K	334,040
2014-03-06	INVAInnoviva, Inc.M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	+12.9K sh	$12.40	+$160K	195,219
2014-03-06	INVAInnoviva, Inc.M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	+29.3K sh	$16.00	+$468K	224,469
2014-03-06	INVAInnoviva, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	−12.9K sh	—	—	0
2014-03-06	INVAInnoviva, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	−29.3K sh	—	—	0
2014-02-20	INVAInnoviva, Inc.F Tax Payment	SVP, Research & Early Clin Dev	FTax Payment	−4,307 sh	$39.98	−$172K	182,316
2014-02-14	INVAInnoviva, Inc.S Sale	SVP, Research & Early Clin Dev	SSale	−30.4K sh	$39.26	−$1.19M	191,223
2014-02-14	INVAInnoviva, Inc.S Sale	SVP, Research & Early Clin Dev	SSale	−4,600 sh	$40.04	−$184K	186,623
2013-11-20	INVAInnoviva, Inc.F Tax Payment	SVP, Research & Early Clin Dev	FTax Payment	−4,569 sh	$36.40	−$166K	222,073
2013-10-03	INVAInnoviva, Inc.G Gift	SVP, Research & Early Clin Dev	GGift	−450 sh	—	—	221,623
2013-08-21	INVAInnoviva, Inc.M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	+18.8K sh	$16.00	+$300K	226,642
2013-08-21	INVAInnoviva, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	−18.8K sh	—	—	0
2013-08-20	INVAInnoviva, Inc.F Tax Payment	SVP, Research & Early Clin Dev	FTax Payment	−3,813 sh	$35.89	−$137K	207,892
2013-07-30	INVAInnoviva, Inc.S Sale	SVP, Research & Early Clin Dev	SSale	−7,000 sh	$36.51	−$256K	211,705
2013-07-24	INVAInnoviva, Inc.A Award	SVP, Research & Early Clin Dev	AAward	+5,000 sh	—	—	218,705
2013-05-29	INVAInnoviva, Inc.M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	+4,570 sh	$3.10	+$14.2K	207,254
2013-05-29	INVAInnoviva, Inc.M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	+6,451 sh	$12.40	+$80K	213,705
2013-05-29	INVAInnoviva, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	−4,570 sh	—	—	0
2013-05-29	INVAInnoviva, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	SVP, Research & Early Clin Dev	MExercise/Conversion	−6,451 sh	—	—	0

Recent filings

Accepted (ET)
Jun 134
Mammen Mathai0001610717-24-000326
SEC(opens sec.gov)
Jun 164
Mammen Mathai0001610717-23-000173
SEC(opens sec.gov)
May 154
Mammen Mathai0001610717-23-000035
SEC(opens sec.gov)
Jun 174
Mammen Mathai0001567619-22-013119
SEC(opens sec.gov)
Feb 174
Mammen Mathai0001225208-22-002372
SEC(opens sec.gov)
Feb 154
Mammen Mathai0001225208-22-002220
SEC(opens sec.gov)
Jun 154
Mammen Mathai0001209191-21-040689
SEC(opens sec.gov)
Jun 174
Mammen Mathai0001209191-20-037270
SEC(opens sec.gov)
Sep 164
Mammen Mathai0000899243-19-023636
SEC(opens sec.gov)

Companies

Address

C/O PARABILIS MEDICINES, INC. 30 ACORN PARK DRIVE, 6TH FLOOR

CAMBRIDGE, MA, 02140